# Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

> **NCT06633757** · PHASE1 · COMPLETED · sponsor: **ReCode Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Primary Ciliary Dyskinesia (PCD)

## Interventions

- **DRUG:** RCT1100

## Key facts

- **NCT ID:** NCT06633757
- **Lead sponsor:** ReCode Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-22
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-02-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06633757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06633757, "Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06633757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*